MTOR and neoplasm: Trials evaluating the combined use of targeted therapies, such as PI3K/mTOR inhibitors with radiation, or immune checkpoint inhibitors alongside chemotherapy, seek to overcome resistance mechanisms and increase tumor vulnerability [46].